Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Occupational Exposure

In the domain of mass production, the legacy of general health and science information has long emphasized broad preventive measures and public awareness of common risk factors. This foundational knowledge, while valuable, often addresses health concerns at a population level without delving into the specific exposures encountered in industrial environments. As manufacturing processes scale, the materials and chemical agents involved can introduce unique health considerations that diverge from general lifestyle or dietary risks. The transition from this general health context to a more focused occupational exposure concern requires acknowledging that workers in production settings may face distinct hazards not captured by standard public health messaging. For instance, the shift from discussing bone health in a universal sense to examining the implications of specific pharmaceutical agents used in industrial or clinical contexts marks a natural progression. This pivot leads to a targeted inquiry: whether exposure to bisphosphonate compounds, such as those found in medications like Fosamax, correlates with elevated risks of jaw-related complications in occupational or clinical populations. The concern here is not about disease mechanisms but about the potential for exposure pathways—whether through direct handling, environmental contamination, or secondary contact—to create a risk profile that warrants separate attention from general health guidance. Thus, the legacy of broad health information serves as a stepping stone to more specialized occupational health assessments.

Fosamax and Osteonecrosis of the Jaw: An Overview

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its primary mechanism involves inhibiting bone resorption, thereby increasing bone mass and reducing fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously or following dental procedures. Clinical presentation typically involves pain, swelling, infection, and delayed healing after tooth extraction or other invasive dental work. The condition can be diagnosed through clinical examination and imaging, with histopathology confirming necrotic bone. Multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanisms Linking Fosamax to ONJ

The mechanistic pathways linking Fosamax to ONJ involve the drug's potent inhibition of osteoclast activity. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress bone remodeling. This suppression can impair the ability of the jawbone to repair microdamage and respond to local infections or trauma, leading to necrosis. Additionally, bisphosphonates may have anti-angiogenic effects, reducing blood supply to the jawbone and further contributing to tissue death. The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Warnings and Risk Factors

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label explicitly states that osteonecrosis of the jaw has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It notes that ONJ can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation and Temporal Relationship

Causation-related considerations for affected patients involve assessing the temporal relationship between Fosamax exposure and ONJ onset. The time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while ONJ is a known adverse effect, its incidence in clinical trials was low and not significantly different from placebo, indicating that other factors, such as underlying dental disease or concurrent medications, may contribute. The timeline between exposure and documented harm can vary widely. ONJ may develop within days to months after starting Fosamax, but the risk appears to increase with longer duration of use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance reflects the balance between therapeutic benefit and potential long-term risks, including ONJ.

Summary of Evidence

In summary, Fosamax is associated with osteonecrosis of the jaw, a serious condition that can occur spontaneously or after dental procedures. The prescribing information provides adequate warnings about this risk, including known risk factors and recommendations for management. Causation is supported by the temporal relationship between exposure and onset, as well as the recurrence upon rechallenge. However, the low incidence in clinical trials and the influence of other risk factors highlight the multifactorial nature of ONJ. Patients and healthcare providers should consider these factors when evaluating the risk-benefit profile of Fosamax therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is Fosamax and how does it work?

Fosamax (alendronate sodium) is a bisphosphonate medication used to treat and prevent osteoporosis. It works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

ONJ is a condition where jawbone tissue dies and becomes exposed, often after dental procedures. Fosamax can cause ONJ by suppressing bone remodeling and reducing blood supply to the jaw. The risk increases with longer use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer, chemotherapy, corticosteroids, poor oral hygiene, periodontal disease, and ill-fitting dentures. Discontinuing Fosamax before dental work may reduce risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.